Trial looks at high intensity focused ultrasound for locally recurrent prostate cancer



As the nation’s growing population of breast cancer survivors ages, many patients will likely develop common chronic illnesses like diabetes and heart disease, and they’ll need specialized care to balance those problems with the late effects of cancer therapies they received. They’ll also need screenings and advice about new strategies for preventing recurrences of their

Full Post: Survivorship care after breast cancer, call for more action

A Phase III clinical trial at New York University is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT) using the Sonablate(R) 500.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, “HIFU using the Sonablate(R) 500 device is a very promising minimally invasive ablative therapy for both the treatment of recurrent prostate cancer following failed external beam radiation therapy and newly diagnosed localized prostate cancer.”

Over 40,000 men with prostate cancer that are treated with radiation have their cancer return every year. These men have few options besides hormone therapy. According to the American Cancer Society possible side effects of hormone therapy include osteoporosis, anemia, loss of muscle mass, depression, decreased mental acuity and impotence.

HIFU with the Sonablate(R) is a minimally invasive, outpatient procedure that uses a transrectal probe to focus ultrasound energy to create a sharp increase in heat within the prostate, thus destroying the tissue. HIFU is radiation free and non surgical. In a small U.S. safety trial, 91% of the participants treated in the trial had a negative biopsy at 6 months.

“We are excited to add NYU to the list of clinical trial sites evaluating the Sonablate(R) 500 for the treatment of recurrent prostate cancer,” said Steve Puckett, Jr., Chief Executive Officer, USHIFU, the company managing the clinical trials with sponsor Focus Surgery, Inc. “The existing treatment options for patients who have recurrent prostate cancer post radiation are limited and often associated with significant quality of life morbidity, so the potential for an alternative therapy is very exciting,” Puckett continued.

Eligible participants for the trial must be between the ages of 40 and 80, have biopsy confirmed local recurrence two or more years following external beam radiation failure (EBRT) and meet several other selection criteria as well.

For more information about enrolling in the HIFU trial calls 1-877-874-4389 or visit www.ProstateCancerRecurrentTrial.org.

This investigational treatment is performed on an outpatient basis. Potential risks of the treatment include frequency, urgency, mild discomfort or discharge in urinary stream. Less common side effects may also include urinary stricture, retention, incontinence, impotence and rectal fistula.

http://www.prostatecancerrecurrenttrial.org/

Link




Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation

Full Post: Proton therapy may reduce serious side effect of lung cancer treatment



In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according

Full Post: First-degree family history of prostate cancer does not affect some treatment outcomes



The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of

Full Post: FDA approves injectable drug degarelix for advanced prostate cancer



The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy. Hormone-related therapy is the first line of treatment for more advanced prostate

Full Post: Theraputic target for prostate cancer



A study published in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Researchers found that noscapine, which has been used in cough medication for nearly 50 years, reduced tumor growth in mice by 60% and

Full Post: Ingredient in cough medicine could treat prostate cancer